Jeyaratnam Caniceus/Pixabay.comThe transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
Irish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.